Multiple Sclerosis: Etiological Mechanisms and Future Directions

Experimental Biology and Medicine

Volumn 229, Issue 1, 2004, Pages 12-20

  Lutton, J D ^a   Winston, R ^a   Rodman, T C ^a,b  

^a CABRINI MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Autoimmune mechanisms; Multiple sclerosis; Myelin basic protein

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTOKINE; GLATIRAMER; METHOTREXATE; MYELIN BASIC PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN EXPRESSION; AUTOIMMUNITY; BLOOD BRAIN BARRIER; BONE MARROW TRANSPLANTATION; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HUMAN; LEUKOCYTE; MULTIPLE SCLEROSIS; PROTEIN STRUCTURE; SHORT SURVEY; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ANIMALIA;

EID: 0345872052     PISSN: 15353702     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020422900102     Document Type: Short Survey

References (94)

1. Weinshenker BC. Epidemiology of multiple sclerosis. Neurol Clin 14(2):291-308, 1996.
2. Claudio L, Kress Y, Factor J, Brosnan CF. Mechanisms of edema formation in experimental autoimmune encephalomyelitis: the contribution of inflammatory cells. Am J Pathol 137:1033-1045, 1990.
3. Miller DH, Rudge P, Johnson G, Kendall BE, Macmanus DG, Moseley IF. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 111:927-939, 1988.
4. Linington C, Bradley M, Lassmann H, Brunner C, Vass K. Augmentation of demyelination in rat allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin oligodendrocyte glycoprotein. Am J Pathol 130:443-454, 1988.
5. Westland KW, Pollard JD, Sander S, Bonner JG, Linington C, McLeod JG. Activated non-neural specific T cells open the blood-brain barrier to circulating antibodies. Brain 122:1283-1291, 1999.
6. Kjima K, Berger T, Lassmann H, Hinze-Selch D, Zhang Y, Gehrmann J. Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100B molecule. J Exp Med 180:817-829, 1994.
7. Carnegie PR. Amino acid sequence of the encephalitogenic basic protein from human myelin. Biochem J 123:57-67, 1971.
8. Eylar EH, Brostoff S, Hashim G, Caccam J, Burnett P. Basic A1 protein of the myelin membrane. The complete amino acid sequence. J Biol Chem 246(18):5770-5784, 1971.
9. Kamholz J, deFerra F, Puckett C, Lazzarini R. Identification of three forms of human myelin basic protein by cDNA cloning. Proc Natl Acad Sci U S A 83(13):4962-4966, 1986.
10. Karthigasan J, Inouye H, Kirschner DA. Implications of the sequence similarities between tau and myelin basic protein. Med Hypotheses 45(3):245-250, 1995.
11. Kirschner DA, Inouye H, Ganser AL, Mann V. Myelin membrane structure and composition correlated: a phylogenetic study. J Neurochem 53(5):1599-1609, 1989.
12. Perez-Gil J, Keough KM. Structural similarities between myelin and hydrophobic surfactant associated proteins: protein motifs for interacting with bilayers. J Theor Biol 169:221-229, 1994.
13. Ridsdale RA, Beniac DB, Tompkins TA, Moscarello MA, Harauz G. Three-dimensional structure of myelin basic protein. J Biol Chem 272(7):4269-4275, 1997.
14. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85:299-302, 1996.
15. Sedzik J, Kirschner DA. Is myelin basic protein crystallizable? Neurochem Res 17(2):157-166, 1992.
16. Boggs JM, Rangaraj G, Koshy KM, Ackerley C, Wood DD, Moscarello MA. Highly deiminated isoform of myelin basic protein from multiple sclerosis brain causes fragmentation of lipid vesicles. J Neurosci Res 57(4):529-535, 1999.
17. Krogsgaard M, Wucherpfennig KW, Canella B, Hansen BE, Svejgaard A, Pyrdol J, Ditzel H, Raine C, Engberg J, Fugger L. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex. J Exp Med 191(8):1395-1412, 2000.
18. Wucherpfennig KW, Sette A, Southwood S, Oseroff C, Matsui M, Strominger JL, Hafler DA. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med 179:279-290, 1994.
19. Scholz C, Patton KT, Anderson DE, Freeman GJ, Hafler DA. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J Immunol 160:1532-1538, 1998.
20. Noseworthy JH. Progress in determining the causes and treatment of multiple sclerosis. Nature 399(24):A40-A47, 1999.
21. Bulman D, Ebers G. The geography of multiple sclerosis reflects genetic susceptibility. J Trop Geogr Neurol 2:66-72, 1992.
22. Dyment DA, Cader MZ, Willer CJ, Risch N, Sadovnick AD, Ebers GC. A multigenerational family with multiple sclerosis. Brain 125(7):1474-1482, 2002.
23. Sawcer S, Goodfellow P, Compston A. The genetic analysis of multiple sclerosis. Trends Genet 13:234-239, 1997.
24. Ebers GC, Bulman DE, Sadovnick AD, Paty DW, Warren S, Hader W, Murray TJ, Seland TP, Duquette P, Grey T. A population-based study of multiple sclerosis in twins. N Engl J Med 315:1638-1642, 1986.
25. Martin R. Genetics of multiple sclerosis-how could disease-associated HLA-types contribute to pathogenesis? J Neural Trans Suppl 49:177-194, 1997.
26. Compston A. The genetics of multiple sclerosis. J Neurovirol 6(2):S5-S9, 2000.
27. Dymet D, Sadovnick A, Ebers G. Genetics of multiple sclerosis. Hum Mol Genet 6:1693-1698, 1997.
28. Laaksonen M, Pastinen T, Sjoroos M, Kuokkanen S, Ruutiainen J, Sumelahti ML, Reijonen H, Salonen R, Wikstrom J, Panelius M, Partanen J, Pentti J, Ilonen J. HLA class II associated risk and protection against multiple sclerosis - a Finnish family study. J Neuroimmunol 122:140-145, 2002.
29. Soldan S, Berti R, Salem N, Secchiero P, Flamand L, Calabresi P. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat Med 3(12):1394-1397, 1997.
30. Salvetti M, Ristori G, Buttinelli C, Fiori P, Falcone M, Britton W, Adams E, Paone G, Grasso MG, Pozzilli C. The immune response to mycobacterial 70-kDa heat shock proteins frequently involves autoreactive T cells and is quantitatively disregulated in multiple sclerosis. J Neuroimmunol 65:143-153, 1996.
31. Shimoji Y, Ng V, Matsumura K, Fischetti VA, Rambukkana A. A 21-kDa surface protein of Mycobacterium leprae binds peripheral nerve laminin-2 and mediates Schwann cell invasion. Proc Natl Acad Sci U S A 96(17):9857-9862, 1999.
32. Merelli E, Bedin R, Sola P, Barozzi P, Mancardi GL, Ficarra G, Franchini G. Human herpes virus 6 and human herpes virus 8 DNA sequences in brains of multiple sclerosis patients, normal adults and children. J Neurol 244(7):450-454, 1997.
33. vanNoort J, van Sechel AC, Bajramovic JJ, el Ouagmiri M, Polman CH, Lassmann H, Ravid R. The small heat-shock protein alpha-beta-crystallin as candidate autoantigen in multiple sclerosis. Nature 375:391-394, 1998.
34. Murray P, McGavern DB, Xiaoqi Lin M, Njenga K, Leibowitz J, Pease LR, Rodriguez M. Perforin-dependent neurologic injury in a viral model of multiple sclerosis. J Neurosci 18:7306-7314, 1998.
35. Cirone M, Cuomo L, Zompetta C, Ruggieri S, Frati L, Faggioni A, Ragona G. Human herpesvirus 6 and multiple sclerosis: a study of T cell cross-reactivity to viral and myelin basic protein antigens. J Med Virol 68:268-272, 2002.
36. Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 19:395-404, 1998.
37. Cermelli C, Jacobson S. Viruses and multiple sclerosis. Viral Immunol 13(3):255-267, 2000.
38. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347(12):911-920, 2002.
39. Rosati G, Aiello I, Mannu L. Incidence of multiple sclerosis in the town of Sassari, Sardinia, 1965-1985: evidence for increasing occurrence of the disease. Neurology 38:384-388, 1988.
40. Poser S, Stickel B, Krtsch U, Burckhardt D, Nordman B. Increasing incidence of multiple sclerosis in South Lower Saxony, Germany. Neuroepidemiology 8:207-213, 1989.
41. Leibowitz U, Antonovsky A, Medalie JM, Smith HA, Halpern L, Alter M. Epidemiological study of multiple sclerosis in Israel. II. Multiple sclerosis and level of sanitation. J Neurol Neurosurg Psychiatry 29:60-68, 1966.
42. Weiss ST. Eat dirt-the hygiene hypothesis and allergic diseases. N Engl J Med 347(12):930-931, 2002.
43. Braun-Fahrlander C, Riedler J, Herz U, Eder W, Waser M, Grize L, Maisch S, Carr D, Gerlach F, Bufe A, Lauener RP, Schierl R, Renz H, Nowak D, von Mutius E. Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med 347(12):869-877, 2002.
44. Tejada-Simon MV, Hong J, Rivera VM, Zhang J. Skewed autoantibody reactivity to the extracellular domain of myelin oligodendrocyte glycoprotein in multiple sclerosis. Immunol 107(4):403-410, 2002.
45. Tejada-Simon MV, Hong J, Rivera VM, Zhang JZ. Reactivity pattern and cytokine profile of T cells primed by myelin peptides in multiple sclerosis and healthy individuals. Eur J Immunol 31:907-917, 2001.
46. Olivares-Villagomez D, Wensky AK, Wang Y, Lafaille JJ. Repertoire requirements of CD4 cells that prevent spontaneous autoimmune encephalomyelitis. J Immunol 164:5499-5507, 2000.
47. Ben-Nun A, Eisenstein S, Cohen IR. Experimental autoimmune encephalomyelitis (EAE) in genetically resistant rats: PVG rats resist active induction of EAE but are susceptible to and can generate EAE effector T cell lines. J Immunol 129:918-925, 1982.
48. Cohen IR. Regulation of autoimmune disease physiological and therapeutic. Immunol Rev 94:5-12, 1986.
49. Fowell D, Mason D. Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes: characterization of the CD4 T cell subsets that inhibits this autoimmune potential. J Exp Med 177:627-639, 1993.
50. Hafler DA, Weiner HL. Immunologic mechanisms and therapy in multiple sclerosis. Immunol Rev 144:75-86, 1995.
51. Ora K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 346:183-185, 1990.
52. Hempel K, Freitag A, Freitag A, Endres B, Mai B, Liebaldt G. Unresponsiveness to experimental allergic encephalomyelitis in Lewis rats pretreated with complete Freund's adjuvant. Int Arch Allergy Appl Immunol 76:193-199, 1985.
53. Qin HY, Sadelain MW, Hitchon C, Lauzon J, Singh B. Complete Freund's adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice. J Immunol 150:2072-2080, 1993.
54. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunesuppression by CD4(+), CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor β. J Exp Med 194:629-644, 2001.
55. Al-Sabbagh A, Miller A, Santos LM, Weiner HL. Antigen-driven tissue specific suppression following oral tolerance: orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL mouse. Eur J Immunol 24;2104-2109, 1994.
56. Weiner HL, Friedman A, Miller A. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 12:809-837, 1994.
57. Soos JM, Hobeika AC, Butfiloski EJ, Schiffenbauer J, Johnson H. Accelerated induction of experimental allergic encephalomyelitis in PL/J mice by a non-V beta 8-specific superantigen. Proc Natl Acad Sci U S A 92:6082-6086, 1995.
58. Soos JM, Schiffenbauer J, Johnson HM. Treatment of PL/J mice with the superantigen, staphylococcal enterotoxin B, prevents development of experimental allergic encephalomyelitis. J Neuroimmunol 43:39-43, 1993.
59. Kim C, Siminovitch KA, Ochi A. Reduction of lupus nephritis in MRL/lpr mice by a bacterial superantigen treatment. J Exp Med 174:1431-1437, 1991.
60. Marie JC, Kehren J, Trescol-Biemont MC. Mechanism of measles virus-induced suppression of inflammatory immune responses. Immunity 14:69-79, 2001.
61. Zinkernagel RM. Maternal antibodies, childhood infections, and autoimmune diseases. N Engl J Med 345:1331-1335, 2001.
62. MacDonald TT, Monteleone G. IL-12 and Th1 immune responses in human Peyer's patches. Trends Immunol 22(5):244-247, 2001.
63. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2:675-680, 2001.
64. Fredrikson S, Sun J, Xiao BG, Link H. Cord blood contains cells secreting antibodies to nervous system components. Clin Exp Immunol 84(2):353-358, 1991.
65. Rodman TC, To SE, Sullivan JJ, Winston R. Innate natural antibodies. Primary roles indicated by specific epitopes. Hum Immunol 55:57-64, 1997.
66. Rodman TC, Sullivan JJ, Bai X, Winston R. The human uniqueness of HIV. Innate immunity and the viral Tat protein. Hum Immunol 60:631-637, 1999.
67. Rodman TC, Lutton JD, Jiang S, Al-Kouatly HB, Winston R. Circulating natural IgM antibodies and their corresponding human cord blood cell-derived Mabs specifically combat the Tat protein of HIV. Exp Hematol 29:1004-1009, 2001.
68. Warrington AE, Asakura K, Bieber AJ, Ciric B, Van Keulen V, Kaveri SV, Kyle RA, Pease LR, Rodriguez M. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci U S A 97(12):6820-6825, 2000.
69. McFarland HI, Lobito AA, Johnson MM, Palardy GR, Yee CSK, Jordan EK, Frank JA, Tresser N, Genain CP, Mueller JP, Matis LA, Lenardo MJ. Effective antigen-specific immunotherapy in the marmoset model of multiple sclerosis. J Immunol 166:2116-2121, 2001.
70. Weiner HL. Oral tolerance for the treatment of autoimmune diseases. Ann Rev Med 48:341-351, 1997.
71. Hohol MJ, Khoury SJ, Cook SL. Three-year open protocol continuation study of oral tolerization with myelin antigens in multiple sclerosis and design of Phase III pivotal trial. In: HL Weiner, LF Mayer, Eds. Oral Tolerance: Mechanisms and Applications. New York: NY Acad Sci, pp243-250, 1996.
72. Weiner HL. Oral tolerance with copolymer 1 for the treatment of multiple sclerosis. Proc Natl Acad Sci U S A 96:3333-3335, 1999.
73. Teitelbaum D, Arnon R, Sela M. Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1. Proc Natl Acad Sci U S A 96:3842-3847, 1999.
74. Miller A, Lider O, Weiner HL. Antigen-driven bystander suppression following oral administration of antigens. J Exp Med 174:791-798, 1991.
75. Aharoni R, Teitelbaum D, Arnon R, Sela M. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci U S A 96:634-639, 1999.
76. Maron R, Slavin AJ, Hoffmann E, Komagata Y, Weiner HL. Oral tolerance to copolymer 1 in myelin basic protein (MBP) TCR transgenic mice: cross-reactivity with MBP-specific TCR and differential induction of anti-inflammatory cytokines. Int Immunol 14(2):131-138, 2002.
77. Soos JM, Stuve O, Youssef S, Bravo M, Johnson HM, Weiner HL, Zamvil SS. Cutting edge: oral type IFN-τ promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate. J Immunol 169:2231-2235, 2002.
78. Lublin FG, Cutter R, Elfont O, Khan R, Lisak H, McFarland H, Panitch J, Noseworthy S, Reingold J, Whitaker J. A trial to assess the safety of combining therapy with interferon β-1α and glatiramer acetate in patients with relapsing MS. Neurology 56(Suppl 3):41-48, 2001.
79. Soos JM, Johnson HM. Interferon tau prospects for clinical use in autoimmune disease. Bio Drugs 11:125-126, 1999.
80. Soos JM, Subramaniam PS, Hobeika AC, Schiffenbauer J, Johnson HM. The IFN pregnancy recognition hormone, IFN-τ, blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity. J Immunol 155:2747-2756, 1995.
81. Soos JM, Mujtaba GM, Subramaniam PS, Streit WJ, Johnson HM. Oral feeding of interferon τ can prevent acute and chronic relapsing forms of experimental allergic encephalomyelitis. J Neuroimmunol 75:43-51, 1997.
82. Olek MJ, Smith DJ, Cook SL, Khoury SJ, Weiner HL. Phase I study of oral recombinant ovine interferon τ in relapsing-remitting multiple sclerosis. Neurology 56(Suppl 3):A76-A77, 2001.
83. Subramanian S, Matejuk A, Zamora A, Vandenbark AV, Offner H. Oral feeding with ethinyl estradiol suppresses and treats experimental autoimmune encephalomyelitis in SJL mice and inhibits the recruitment of inflammatory cells into the central nervous system. J Immunol 170:1548-1555, 2003.
84. Kumpfel T, Heydari N, Holfeld R. Antegren (natalizumab). A promising new approach to therapy of multiple sclerosis. Nervenarzt 73(6):552-555, 2002.
85. Miller DH, Khan OA, Sheremuta WA, Blumhardt LD, Rice GPA, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Connor PW. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348(1):15-23, 2003.
86. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rusk-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S. Natalizumab for active Crohn's Disease. N Engl J Med 348(1):24-32, 2003.
87. Openshaw H. Conference synopsis: hematopoietic stem cell therapy in autoimmune diseases. Bio Blood Marrow Transpl 8:407-411, 2002.
88. Fassas A. Autologous stem cell transplants in treatment of multiple sclerosis: where we stand and future prospects. Int J Hematol 76(Suppl 1):223-225, 2002.
89. Fassas A, Passweg JR, Anagnostopoulos A, Kazis A, Kozak T, Havrdova E, Carreras E, Graus F, Kashyap A, Openshaw H, Schipperus M, Deconinck E, Mancardi G, Marmont A, Hansz J, Rabusin M, Zuazu NFJ, Besalduch J, Dentamaro T, Fouillard L, Hertenstein B, LaNasa G, Musso M, Papineschi F, Rowe JM, Saccardi R, Steck A, Kappos L, Gratwohl A, Tyndall A. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 249(8):1088-1097, 2002.
90. Welte T, Zhang SM, Wang T, Zhang Z, Hesslein DT, Yin Z, Kano A, Iwamoto Y, Li E, Craft JE, Bothwell AM, Fikrig E, Koni PA, Flavell RA, Fu XY. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci U S A 100(4):1879-1884, 2003.
91. Madsen LS, Andersson EC, Jansson L, Krogsgaard M, Andersen CB, Engberg J, Strominger JL, Sevjgaard A, Hjorth JP, Holmdahl R, Wucherpfennig KW, Fugger L. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat Genet 23:343-347, 1999.
92. Sorensen PS. The role of intravenous immunoglobulin in the treatment of multiple sclerosis. J Neurol Sci 206(2):123-130, 2003.
93. Brod SA. Ingested type I interferon: a potential treatment for autoimmunity. J Interferon Cytokine Res 22(12):1153-1166, 2002.
94. Fujino M, Funeshima N, Kitazawa Y, Kimura H, Amemiya H, Suzuki S, Li XK. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 305(1):70-77, 2003.